Inhlanganisela yePilisi yeHIV phakathi kweNinzi echazwe kwihlabathi jikelele
Ukwahlula
I-Atripla yipilisi enye, i-dose edibeneyo ye-dose (FDC) enezi- antiretroviral ezintathu: i-tenofovir, i-emtricitabine ne-efavirenz.
I-Tenofovir kunye ne-emtricitabine zombini ihlelwa njenge- nucleotide reverse transcriptase inhibitors kwaye zizithengiswa ngokuzimela njenge- Viread (i-tenofovir) , i-Emtriva (emtricitabine, i-FTC) kunye ne-FDC Truvada (Tenovfovir + emtricitabine).
U-Efavirenz, ngokuchaseneyo, yi- non-nucleoside reverse transcriptase inhibitor kwaye ithengiswa ngezorhwebo njengoSusva (efavirenz) .
I-Atripla yayisenisiqinisekiso se-US Food and Drug Administration (i-FDA) ngo-Juni 12, 2012 kwaye yayisisigxina sokuqala sosuku, sesithathu kwisinye esivunyelwe ukusebenzisa unyango lwe-HIV kubantu abadala kunye nabantwana abaneminyaka eli-12 nangaphezulu.
Kuze kube ngo-2015, i-Atripla yayimiswe njengolukhethiweyo, unyango lokuqala lwe-HIV e-US, malunga neyesithathu kwisigidi sazo zonke izigulane ezibekwe izilwanyana. Izidakamizwa ezisandul 'ukuza kutshanje (ezaziqhayisa ngokubambisana kunye nokuzinza okungcono) ekugqibeleni zathintela uApripla kwiluhlu "olucetyiswayo" lwezonyango "
Okwangoku akukho nhlobo ye-generic e-Atripla e-US
UkuQulunqa kweAtripla
I-Atripla i-tablet efomatiweyo eyenziwe nge-300mg tenofovir disoproxil fumarate, i-200mg emtricitabine kunye ne-600mg ye-efavirenz.
Ipinki, i-oblong tablet yenziwe ngefestile kwaye igxinwe kwelinye icala kunye nenombolo "123."
Isripla Isisombululo
Kubantu abadala kunye nabantwana abaneminyaka engama-12 okanye ngaphezulu abalinganisa ubunzima be-87 lbs (40kg): enye ithebhulethi ithathwa ngomlomo kwisisu esingenalutho, ngokufanelekileyo ngexesha lokulala (ngenxa yongxowankulu onokuvela ngenxa yecandelo le-efavirenz).
Izigulane ezithatha i-rifampin (ezisetyenziselwa rhoqo unyango lwe-tuberculosis coinfection) ezilinganisa ubuncinane i-110 lbs (50kg): Ithebhulethi enye ye-Atripla kunye nebhebhethi enye ye-Sustiva (efavirenz) isetyenziswe ngomlomo, kwakhona kwisisu esingenalutho kwaye ngexesha lokulala.
Atripla Side Effects
Iziphumo eziqhelekileyo ezichaphazelekayo nokusetyenziswa kwe-Atripla (okwenzeka okungenani ama-5% amatyala) ziquka:
- I sizathu
- Uhudo
- Ukukhathala
- Sinusitis
- Intloko
- Utywala
- Ukuxinezeleka
- Ukungabikho
- Amaphupha angaqhelekanga
- Rash
Uninzi lweempawu zihlala zifutshane, zihlala zizixazulula ngokwayo ngeveki okanye ezimbini. Ezinye zeendlela eziphazamisayo zesistim, njengesizondlo, ngamanye amaxesha kuthatha ixesha elide ukulungisa, nangona kuthatha iipilisi ebusuku, ngaphambi kokulala, kunciphisa kakhulu iimpawu.
Ukungqinelana
- Amachiza antifungal: Vrend (voriconazole)
- Imithi ye-Hepatitis B: I-Hepsera (adefovir)
- Izixhobo ezivela e-Ergot (kuquka iWigraine neCafergot)
- I-block blockil ye-calcium: i-Vascor (bedripil), i-Propulsid (cisapride), i-Orap (i-pimozide)
- ISt John's Wort
Ingqwalasela yonyango
Izigulane eziye zazibona zangaphambili, ezinamandla ukuphendula kwiSustiva (kubandakanywa ukukhawuleza okugqithisileyo okanye okuphazamisekayo) akufaneleki i-Atripla.
I-Atripla kufuneka isetyenziswe ngononophelo kwizigulane ezineembali zentsiba (isifo).
Soloko uvavanya imvume yokudala i-creinine ngaphambi kokuba uqalise unyango. Kwizigulane ezinobungozi bokungasebenzi kwemfucuza, zibandakanya imvume yokudalwa kwemveli, i-serum phosphorus, i-urine glucose kunye neprotein yamanzi xa iliso. I-Atripla ayifanele isetyenziswe kwizigulane ezinegunya lokuqikelela elidaliweyo elingaphantsi kwe-50mL / ngomzuzu.
Ukujonga izilingo zomsebenzi wesibindi kwizigulane ze-hepatic ezinezifo zesibindi, kuquka i- hepatitis B kunye ne- hepatitis C. I-Atripla ayikhuthazwa kwizigulane ezinomlinganiselo othe tyeleleko kwesibindi esinamandla. Sebenzisa ngokulumkileyo kwizigulane ezinobunzima obunobumba.
Icandelo le-efavirenz e-Atripla lidibaniswe nokungaqhelekanga kwe-fetal kwinani lezifundo zezilwanyana.
Nangona kusekho ukungqubana nokuba i-efavirenz ibeka nayiphi na ingozi ebomini kubantu, kucetyiswa ukuba iAtripla igwenywe ngexesha lokukhulelwa ), ingakumbi ngexesha lekota yokuqala. Oomama banconywa ukuba bangalusanga xa bethatha iAtripla.
I-Atripla kufuneka imiselwe ngokulumkisa kubantu ababethekile, kunye nalabo abane-schizophrenia, uxinzelelo lwekliniki okanye ezinye iingxaki zengqondo. Icandelo le-efavirenz liyaziwa ukuba lichaphazeleke kwinkqubo yesantya ephakathi, okubangelwa ukungcola, amaphupha acacileyo, ukungaqiniseki kunye nokuphazamiseka kwabanye abantu.
Imithombo:
US Administration and Drug Administration (FDA). "I-FDA iyavuma okokuqala I-Day-Day-Day-Day-Day Combination Treatment of HIV-1." Silver Spring, eMaryn; ukukhutshwa kwenkcazelo ekhutshwe ngo-Agasti 2, 2004.
Bristol Myers Squibb. " Iimbali eziphambili zokuLawulwa kolwazi - ATRIPLA ." 2006.